143 related articles for article (PubMed ID: 31058344)
1. Simvastatin enhances chemotherapy in cervical cancer via inhibition of multiple prenylation-dependent GTPases-regulated pathways.
Pan Q; Xu J; Ma L
Fundam Clin Pharmacol; 2020 Feb; 34(1):32-40. PubMed ID: 31058344
[TBL] [Abstract][Full Text] [Related]
2. HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation.
Al-Haidari AA; Syk I; Thorlacius H
Biochem Biophys Res Commun; 2014 Mar; 446(1):68-72. PubMed ID: 24582560
[TBL] [Abstract][Full Text] [Related]
3. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation.
Blanco-Colio LM; Villa A; Ortego M; Hernández-Presa MA; Pascual A; Plaza JJ; Egido J
Atherosclerosis; 2002 Mar; 161(1):17-26. PubMed ID: 11882313
[TBL] [Abstract][Full Text] [Related]
4. Ras inhibition by zoledronic acid effectively sensitizes cervical cancer to chemotherapy.
Xu J; Pan Q; Ju W
Anticancer Drugs; 2019 Sep; 30(8):821-827. PubMed ID: 30882399
[TBL] [Abstract][Full Text] [Related]
5. Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases.
Zhu Y; Casey PJ; Kumar AP; Pervaiz S
Cell Death Dis; 2013 Apr; 4(4):e568. PubMed ID: 23559002
[TBL] [Abstract][Full Text] [Related]
6. 3-Hydroxymethyl coenzyme A reductase inhibition attenuates spontaneous smooth muscle tone via RhoA/ROCK pathway regulated by RhoA prenylation.
Rattan S
Am J Physiol Gastrointest Liver Physiol; 2010 Jun; 298(6):G962-9. PubMed ID: 20378830
[TBL] [Abstract][Full Text] [Related]
7. HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway.
Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
Biochem Biophys Res Commun; 2008 Sep; 374(2):309-14. PubMed ID: 18625202
[TBL] [Abstract][Full Text] [Related]
8. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA.
Park HJ; Kong D; Iruela-Arispe L; Begley U; Tang D; Galper JB
Circ Res; 2002 Jul; 91(2):143-50. PubMed ID: 12142347
[TBL] [Abstract][Full Text] [Related]
9. Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase.
Kato S; Smalley S; Sadarangani A; Chen-Lin K; Oliva B; Brañes J; Carvajal J; Gejman R; Owen GI; Cuello M
J Cell Mol Med; 2010 May; 14(5):1180-93. PubMed ID: 19432822
[TBL] [Abstract][Full Text] [Related]
10. Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation.
Lee MH; Cho YS; Han YM
Stem Cells; 2007 Jul; 25(7):1654-63. PubMed ID: 17464088
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin suppresses leptin expression in 3T3-L1 adipocytes via activation of the cyclic AMP-PKA pathway induced by inhibition of protein prenylation.
Maeda T; Horiuchi N
J Biochem; 2009 Jun; 145(6):771-81. PubMed ID: 19254925
[TBL] [Abstract][Full Text] [Related]
12. The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer.
Stine JE; Guo H; Sheng X; Han X; Schointuch MN; Gilliam TP; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Jan; 7(1):946-60. PubMed ID: 26503475
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases.
Ghittoni R; Patrussi L; Pirozzi K; Pellegrini M; Lazzerini PE; Capecchi PL; Pasini FL; Baldari CT
FASEB J; 2005 Apr; 19(6):605-7. PubMed ID: 15677697
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin Reduces Cancerogenic Potential of Renal Cancer Cells via Geranylgeranyl Pyrophosphate and Mevalonate Pathway.
Woschek M; Kneip N; Jurida K; Marzi I; Relja B
Nutr Cancer; 2016; 68(3):420-7. PubMed ID: 27042994
[TBL] [Abstract][Full Text] [Related]
15. Vorinostat and Simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation.
Kou X; Yang Y; Jiang X; Liu H; Sun F; Wang X; Liu L; Liu H; Lin Z; Jiang L
Eur J Pharmacol; 2017 Oct; 813():161-171. PubMed ID: 28826913
[TBL] [Abstract][Full Text] [Related]
16. The bisphosphonate zoledronic acid effectively targets lung cancer cells by inhibition of protein prenylation.
Xie F; Li P; Gong J; Zhang J; Ma J
Biochem Biophys Res Commun; 2015 Nov; 467(4):664-9. PubMed ID: 26498526
[TBL] [Abstract][Full Text] [Related]
17. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase.
Schmidmaier R; Baumann P; Simsek M; Dayyani F; Emmerich B; Meinhardt G
Blood; 2004 Sep; 104(6):1825-32. PubMed ID: 15161667
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of simvastatin on mesangial cells.
Heusinger-Ribeiro J; Fischer B; Goppelt-Struebe M
Kidney Int; 2004 Jul; 66(1):187-95. PubMed ID: 15200425
[TBL] [Abstract][Full Text] [Related]
19. Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells.
Gbelcová H; Rimpelová S; Knejzlík Z; Šáchová J; Kolář M; Strnad H; Repiská V; D'Acunto WC; Ruml T; Vítek L
Lipids Health Dis; 2017 Dec; 16(1):250. PubMed ID: 29262834
[TBL] [Abstract][Full Text] [Related]
20. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy.
Danesh FR; Sadeghi MM; Amro N; Philips C; Zeng L; Lin S; Sahai A; Kanwar YS
Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8301-5. PubMed ID: 12048257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
